BioCentury
ARTICLE | Financial News

NGM could get $975M valuation in NASDAQ IPO

March 26, 2019 6:48 PM UTC

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range.

The valuation includes a concurrent private placement of 4.1 million shares to partner Merck & Co. Inc. (NYSE:MRK), which would own 19.9% of NGM Biopharmaceuticals Inc. (South San Francisco, Calif.)...